# Response to the Editor — ATIS-D-26-00459 (revised)

Dear Editor,

Thank you for assessing the manuscript and for the invitation to revise. Both concerns have
been addressed directly, and I am grateful for the steer — the paper is better focused for it.

**1. Focus on how Observer Zero supports problem-solving on real-world problems.** The
manuscript has been reframed around its applied purpose: evaluating whether an autonomous
agent system is ready for real-world investigative work, with healthcare and drug discovery
as the motivating domains throughout.

- The Introduction now opens on the deployment settings themselves — monitoring
  pharmacovigilance and clinical-trial data for safety signals, running autonomous experiment
  loops in drug discovery, maintaining infrastructure — and states the deployer's question
  the paper operationalises: when such a system fails, does it fail at sensing or at
  reasoning, and would more data help?
- The platform contribution is now presented explicitly as a rehearsal environment in which
  an agent system can be evaluated against covert change before it is trusted with a real
  problem.
- The Discussion's "Implications for deployed multi-agent systems" section gains a concrete
  pre-deployment protocol: run the candidate system in an instrumented rehearsal world whose
  laws change covertly on the experimenter's schedule; the three-level decomposition then
  localises any failure to measurement policy, data quantity, or inference — each with a
  different remedy — and the contamination result supplies a fourth pre-deployment check for
  multi-agent pipelines in these domains.
- The Abstract now closes on these settings.

The revision is careful not to overclaim: the paper's position is that Observer Zero is how
one finds out whether an agent system is ready for problems in healthcare or drug discovery,
not that it solves those problems itself.

**2. Tone regarding confirmatory design and other studies.** Language that could read as
criticism of other groups' work has been removed throughout. The bolded claim that "existing
evaluations rarely distinguish" the two failure modes is gone (the point is now stated as a
property of outcome-only scoring, not a failing of colleagues); the section formerly titled
"Pre-registration and the discipline actually applied" is retitled "Design freeze and
pre-registration" and presented plainly as the study's internal quality control; and the
passages that quoted audit statistics about validity violations in the field have been
replaced with a positive statement of the design principles this study follows. The
pre-registration content itself is retained, since reviewers will need it to assess the
confirmatory claims, but it is reported as method, not advocacy.

**In addition**, the manuscript has been condensed: the pre-registered decision table is cut
from ten rows to the four that constrained decisions (the full table remains in the deposited
artifacts), the validity table is now a short paragraph, and the related-work and results
narration have been tightened throughout. No result, number, or limitation has been removed.

I hope the revised manuscript is now suitable for review, and I would be happy to make any
further adjustments the editors consider necessary.

Yours sincerely,

Nick Lamb
Independent Researcher, Oxford, United Kingdom
ORCID: 0009-0009-6266-8499 · nick@pharmatools.ai
